Serena Laura Orr

Serena Laura Orr

Auto-generated profile, based on publicly available information

Serena Laura Orr

Department of Pediatrics, Cumming School of Medicine University of Calgary Calgary Alberta Canada

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2016 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Closed access
PDF file
SOSerena L. Orr
Serena L. Orr
BFBenjamin W. Friedman
Benjamin W. Friedman
SCSuzanne Christie
Suzanne Christie
MMMia T. Minen
Mia T. Minen
CBCynthia Bamford
Cynthia Bamford
DTDeborah Tepper
Deborah Tepper

29 May 2014 in Cephalalgia
Verified
Journal Article
Closed access
SOSerena L Orr
Serena L Orr
MAMichel Aubé
Michel Aubé
WBWerner J Becker
Werner J Becker
WDW Jeptha Davenport
W Jeptha Davenport
EDEsma Dilli
Esma Dilli
SCSuzanne N Christie
Suzanne N Christie
Background: There is a considerable amount of practice variation in managing migraines in emergency settings, and evidence-based therapies are often not used first line. Methods: A peer-reviewed search of databases (MEDLINE, Embase, CENTRAL) was carried out to identify randomized and quasi-randomized controlled trials of interventions for acute pain relief in adults presenting with migraine to emergency settings. Where possible, data were pooled into meta-analyses. Results: Two independent reviewers screened 831 titles and abstracts for eligibility. Three independent reviewers subsequently evaluated 120 full text articles for inclusion, of which 44 were included. Individual studies were then assigned a US Preventive Services Task Force quality rating. The GRADE scheme was used to assign a level of evidence and recommendation strength for each intervention. Interpretation: We strongly recommend the use of prochlorperazine based on a high level of evidence, lysine acetylsalicylic acid, metoclopramide and sumatriptan, based on a moderate level of evidence, and ketorolac, based on a low level of evidence. We weakly recommend the use of chlorpromazine based on a moderate level of evidence, and ergotamine, dihydroergotamine, lidocaine intranasal and meperidine, based on a low level of evidence. We found evidence to recommend strongly against the use of dexamethasone, based on a moderate level of evidence, and granisetron, haloperidol and trimethobenzamide based on a low level of evidence. Based on moderate-quality evidence, we recommend weakly against the use of acetaminophen and magnesium sulfate. Based on low-quality evidence, we recommend weakly against the use of diclofenac, droperidol, lidocaine intravenous, lysine clonixinate, morphine, propofol, sodium valproate and tramadol.

15 October 2018 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Open access
PDF file
CSChristina L. Szperka
Christina L. Szperka
JVJuliana VanderPluym
Juliana VanderPluym
SOSerena L. Orr
Serena L. Orr
COChristopher B. Oakley
Christopher B. Oakley
WQWilliam Qubty
William Qubty
AGAmy A. Gelfand
Amy A. Gelfand

1 December 2022 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
KFKatherine Falla
Katherine Falla
JKJonathan Kuziek
Jonathan Kuziek
SMSyeda Rubbia Mahnaz
Syeda Rubbia Mahnaz
MNMelanie Noel
Melanie Noel
PRPaul E. Ronksley
Paul E. Ronksley
SOSerena L. Orr
Serena L. Orr
One in 10 children and adolescents experience migraine1,2 and, across the life span, it is the second most prevalent and disabling disease worldwide.3 The optimal management of migraine in children and adolescents comprises a multimodal approach that combines evidence-based acute treatment, preventive treatment where indicated, education, identification, and treatment of comorbid disorders.4,5

23 July 2018 in Nature Reviews Neurology
Verified
Journal Article
Open access
PDF file
SOSerena L. Orr
Serena L. Orr
MKMarielle A. Kabbouche
Marielle A. Kabbouche
HOHope L. O’bRien
Hope L. O’bRien
JKJoanne Kacperski
Joanne Kacperski
SPScott W. Powers
Scott W. Powers
AHAndrew D. Hershey
Andrew D. Hershey
Migraine is prevalent in children and adolescents and constitutes an important cause of disability in this population. Early, effective treatment of paediatric migraine is likely to result in improved outcomes. Findings from the past few years suggest that a biopsychosocial approach that uses interdisciplinary multimodal care is most effective for treatment of migraine in the paediatric population. Key elements of this management include effective and timely acute pharmacological interventions (such as NSAIDs and/or triptans), education of patients regarding self-management techniques, and psychological interventions such as biofeedback, relaxation and cognitive–behavioural therapy. The efficacy of current pharmacological or nutraceutical interventions for migraine prevention in children and adolescents is unclear, although reported placebo response patterns suggest that the effect of pill-taking behaviour is positive. As such, clinicians can consider adding a preventive intervention that involves a daily pill-taking behaviour to evidence-based non-pharmacological first-line preventive interventions (such as cognitive–behavioural therapy). More rigorous research is needed to delineate the role of pharmacological and nutraceutical interventions, the mechanisms of the clinically relevant placebo response, and interventions that enhance this response for migraine prevention in this population. Given the prevalence of migraine, cost-effective and efficacious strategies are needed for the large-scale delivery of interdisciplinary multimodal paediatric migraine care.

18 November 2014 in Journal of Child Neurology
Verified
Journal Article
Closed access
TSTrevor A. Seeger
Trevor A. Seeger
SOSerena Orr
Serena Orr
LBLisa Bodell
Lisa Bodell
LLLisette Lockyer
Lisette Lockyer
TRThilinie Rajapakse
Thilinie Rajapakse
KBKaren M. Barlow
Karen M. Barlow
Posttraumatic headache is one of the most common and disabling symptoms after traumatic brain injury. However, evidence for treating posttraumatic headache is sparse, especially in the pediatric literature. This retrospective chart review evaluated the use of occipital nerve blocks in adolescents treated for posttraumatic headache following mild traumatic brain injury, presenting to the Complex Concussion and Traumatic Brain Injury clinic. Fifteen patients (mean age 15.47; range: 13-17) received occipital nerve block for posttraumatic headache. Follow-up was obtained in 14 patients at 5.57 (standard deviation = 3.52) months postinjury. The headache burden was high, with all except one having headaches 15 or more days per month (median 30, range 10-30). Sixty-four percent reported long-term response to the occipital nerve blocks, with associated improved quality of life and decreased postconcussion symptom scores (P < .05). One patient reported transient allopecia. Occipital nerve blocks are well tolerated and can be helpful in posttraumatic headache.